Myeloma News and Research RSS Feed - Myeloma News and Research

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges. [More]
TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center. [More]
Residential radon exposure may lead to hematologic cancer risk in women

Residential radon exposure may lead to hematologic cancer risk in women

A new report finds a statistically-significant, positive association between high levels of residential radon and the risk of hematologic cancer (lymphoma, myeloma, and leukemia) in women. The study is the first prospective, population-based study of residential radon exposure and hematologic cancer risk, leading the authors to caution that it requires replication to better understand the association and whether it truly differs by sex. It appears early online in Environmental Research. [More]
Series of routine tests may not be beneficial to patients with age-related disorder

Series of routine tests may not be beneficial to patients with age-related disorder

A series of tests physicians routinely order to help diagnose and follow their patients with an elevated antibody level that is a marker for cancer risk, often do not benefit the patient but do increase health care costs, pathologists report. [More]
Study on HDAC enzymes could lead to development of better drugs for treatment of cancer, Alzheimer’s

Study on HDAC enzymes could lead to development of better drugs for treatment of cancer, Alzheimer’s

New knowledge about the mechanism of specific protein complexes in the body could help in the development of better drugs for the treatment of diseases such as cancer and Alzheimer’s, according to research led by the University of Leicester. [More]
Rab inhibition may be a promising antimyeloma strategy

Rab inhibition may be a promising antimyeloma strategy

Roswell Park Cancer Institute researchers are investigating agents that target and disrupt the trafficking of monoclonal antibodies in multiple myeloma, a cancer of the bone marrow. The results will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans. [More]
PPP3CA, calcineurin may be suitable therapeutic targets for multiple myeloma treatment

PPP3CA, calcineurin may be suitable therapeutic targets for multiple myeloma treatment

Multiple myeloma (MM) is a hematological cancer that frequently acquires resistance to chemotherapeutic drugs. Additionally, many patients experience disease relapse, but these patients are difficult to treat as the cancer is often resistant to the previous treatment regimen. [More]
BCR-ABL halving time indicates CML prognosis during front-line TKI

BCR-ABL halving time indicates CML prognosis during front-line TKI

Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers. [More]
Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

New research from Roswell Park Cancer Institute shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse large B-cell lymphoma (DH-DLBCL) in preclinical studies. The researchers will present their findings at the American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16-20 in New Orleans. [More]
Imatinib-related symptom burden linked to adherence in Indian CML patients

Imatinib-related symptom burden linked to adherence in Indian CML patients

Research shows low adherence to imatinib in Indian patients with chronic myeloid leukaemia, with an association between nonadherence and worse symptom burden related to treatment. [More]
Radiotherapy needs likely to increase in all European countries by 2025

Radiotherapy needs likely to increase in all European countries by 2025

The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology. [More]
Medi-551 antibody treatment decreases number of cancer stem cells by half in multiple myeloma patients

Medi-551 antibody treatment decreases number of cancer stem cells by half in multiple myeloma patients

An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists. [More]
Binding Site to collarborate in iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial

Binding Site to collarborate in iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial

Binding Site is proud to be a key collaborator with Prof Sigurdur Kristinsson of the University of Iceland in his pivotal MGUS screening study for the forthcoming iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial. [More]
CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the granting of a conditional marketing authorisation for first-in-class CD38 immunotherapy daratumumab in the European Union. [More]
Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

PharmaMar today announced positive top-line results of its Phase III clinical trial -ADMYRE- with Aplidin (plitidepsin) in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM). [More]
UAM implements family-centered care model to provide better patient outcomes

UAM implements family-centered care model to provide better patient outcomes

Family presence when a child is undergoing tracheal intubation in a pediatric intensive care unit (PICU) can safely be implemented as part of a family-centered care model, reported a research team led by a University of Arkansas for Medical Sciences professor in the March 7 issue of JAMA Pediatrics. [More]
Cinqair (reslizumab) approved for treatment of severe asthma

Cinqair (reslizumab) approved for treatment of severe asthma

The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. [More]

Researchers describe generation of plasma cell-specific antibody from immunized lampreys

Antibody-secreting plasma cells arise from B cell precursors and are essential for adaptive immune responses against invading pathogens. Plasma cell dysfunction is associated with autoimmune and neoplastic disorders, including multiple myeloma. [More]
Vascular events in CML may not be linked to TKI therapy

Vascular events in CML may not be linked to TKI therapy

The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest. [More]
Psoriasis patients experience widespread bone loss

Psoriasis patients experience widespread bone loss

Researchers from the Genes, Development and Disease Group, headed by Erwin Wagner at the Spanish National Cancer Research Centre have discovered that psoriasis patients experience a widespread bone loss as a result of the disease. [More]
Advertisement
Advertisement